Travel Medicine and Infectious Disease
Volume 7, Issue 4 , Pages 231-234 , July 2009

Serogroup B meningococcal disease during Hajj: Preparing for the worst scenario

  • Mohamed K.M. Khalil

      Affiliations

    • Medical Research, Ministry of Health, Riyadh, Saudi Arabia
    • Tel.: +966 504955087.
    • ,
  • Ray Borrow

      Affiliations

    • Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 161 276 6793; fax: +44 161 276 6792.

Received 7 July 2009 ,Revised 14 July 2009 ,Accepted 16 July 2009.

References 

  1. Caugant DA. Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infect Genet Evol. 2008;8:558–565
  2. Apicella MA. Neisseria meningitidis. In: Mandell , Douglas , Bennett  editor. Principles and practice of infectious diseases. 5th ed.. Churchill Livingstone; 2000;p. 2228–2241
  3. Wilder-Smith A. Meningococcal disease: risk for international travelers and vaccine strategies. Travel Med Infect Dis. 2008;6:182–186
  4. Greenwood B. The changing face of meningococcal disease in West Africa. Epidemiol Infect. 2007;135:703–705
  5. Wang JF, Caugant DA, Li X, Hu X, Poolman JT, Crowe BA, et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun. 1992;60:5267–5282
  6. Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093–1096
  7. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14:195–207
  8. Cruz C, Pavez G, Aguilar E, Grawe L, Cam J, Mendez F, et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect. 1990;1990(105):119–126
  9. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis. 1998;177:497–500
  10. Molding P, Buckhman A, Olcen P, Fredlund H. Comparison of serogroup W135 meningococci isolated in Sweden during a 23-year period and those associated with a recent Hajj pilgrimage. J Clin Microbiol. 2001;39:2695–2699
  11. Al-Mazrou YY, Al-Jeffri MH, Abdalla MN, Elgizouli SA, Mishskas AA. Changes in epidemiological pattern of meningococcal disease in Saudi Arabia. Does it constitute a new challenge for prevention and control?. Saudi Med J. 2004;25:1410–1413
  12. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis. 2003;36:679–683
  13. Balkhy HH, Memish ZA, Osoba AO. Meningococcal carriage among local inhabitants during the pilgrimage 2000–2001. Int J Antimicrob Agents. 2003;21:107–111
  14. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Maïnassara HB, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44:657–663
  15. Balkhy HH, Memish ZA, Almuneef MA, Osoba AO. Neisseria meningitidis W-135 carriage during the Hajj season 2003. Scand J Infect Dis. 2004;36:264–268
  16. Karima TM, Bukhari SZ, Fatani MI, Yasin KA, Al-Afif KA, Hafiz FH. Clinical and microbiological spectrum of meningococcal disease in adults during Hajj 2000: an implication of quadrivalent vaccination policy. J Pak Med Assoc. 2003;53:3–7
  17. El Bushra HE, Hassan NM, Al-Hamdan NA, Al-Jeffri MH, Turkistani AM, Al-Jumaily A, et al. Determinants of case fatality rates of meningococcal disease during outbreaks in Makkah, Saudi Arabia, 1987–97. Epidemiol Infect. 2000;125:555–560
  18. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet. 1983;322:355–357
  19. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007;166:817–823
  20. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999;281:1520–1527
  21. Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16–24 months. Pediatr Infect Dis J. 2007;26:345–350
  22. Cartwright KAV, Richmond P, Morris R, Rümke H, Fox AJ, Borrow R, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 outer membrane proteins. Vaccine. 1999;17:2612–2619
  23. Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287:1816–1820
  24. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3:445–450
  25. Miller E, Pollard AJ, Borrow R, Findlow J, Dawson T, Morant A, et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine after three doses administered in infancy. In: 26th Meeting of the European Society for Paediatric Infectious Diseases – ESPID, Graz, Austria, 14th May 2008.
  26. Block C, Roitman M, Bogokowsky B, Meizlin S, Slater PE. Forty years of meningococcal disease in Israel: 1951–1990. Clin Infect Dis. 1993;17:126–132
  27. Greif Z, Schiab S, Leitner L. [Meningococcal disease in western Galilee]. Harefuah. 1992;122:221–223
  28. Stein-Zamir C, Abramson N, Zentner G, Shoob H, Valinsky L, Block C. Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect. 2008;136:782–789
  29. Girard MP, Preziosi MP, Aquado MT, Kieny MP. A review of vaccine research and development: meningococcal diseases. Vaccine. 2006;24:4692–4700
  30. Ahmed QA, Arabi YM, Memish ZA. Health risks at the Hajj. Lancet. 2006;367:1008–1015
  31. Tourism statistics 2007. Saudi Arabia: MAS, Tourism Information and Research Center; 2009;
  32. Nakhla I, Frenck RW, Teleb NA, El Oun S, Mansour H, Mahoney F. The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination program in Egypt. Vaccine. 2005;23:3288–3293
  33. Afifi S, Wasfy MO, Azab MA, Youssef FG, Pimentel G, Graham TW, et al. Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998–2004). Eur J Clin Microbiol Infect Dis. 2007;26:331–340
  34. Ceyhan M, Yildirim I, Balmer P, Borrow R, Dikici B, Turgut M, et al. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis. 2008;14:1089–1096

PII: S1477-8939(09)00120-3

doi: 10.1016/j.tmaid.2009.07.001

Travel Medicine and Infectious Disease
Volume 7, Issue 4 , Pages 231-234 , July 2009

Article Tools

* Image Usage & Resolution